Last updated on April 2018

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)


Brief description of study

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Clinical Study Identifier: NCT02615002

Contact Investigators or Research Sites near you

Start Over

Neurim Pharmaceuticals, Ltd.

The Roskamp Institute, Inc
Sarasota, FL United States
3.67miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.